M. Assié

发表

Effects of prolonged administration of milnacipran, a new antidepressant, on receptors and monoamine uptake in the brain of the rat

C. Palmier, M. Briley, C. Puozzo, 1992, Neuropharmacology.

Differential in vivo Inhibition of [3H]Nemonapride Binding by Atypical Antipsychotics in Rat Striatum, Olfactory Lobes, and Frontal Cortex

A. Newman-Tancredi, W. Koek, M. Assié, 2005, Pharmacology.

[(3)H]-8-OH-DPAT binding in the rat brain raphe area: involvement of 5-HT(1A) and non-5-HT(1A) receptors.

W. Koek, M. Assié, 2000, British journal of pharmacology.

Biphasic displacement of [3H]YM-09151-2 binding in the rat brain by thioridazine, risperidone and clozapine, but not by other antipsychotics.

W. Koek, A. Sleight, M. Assié, 1993, European journal of pharmacology.

Benzodiazepine agonist-type activity of raubasine, a rauwolfia serpentina alkaloid.

M. Briley, M. Charvéron, A. Stenger, 1984, European journal of pharmacology.

Design and synthesis of a series of 6-substituted-2-pyridinylmethylamine derivatives as novel, high-affinity, selective agonists at 5-HT1A receptors.

W. Koek, C. Cosi, B. Bonnaud, 1998, Journal of medicinal chemistry.

F15063, a potential antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice

R. Depoortère, A. Newman-Tancredi, F. Sautel, 2007, Naunyn-Schmiedeberg's Archives of Pharmacology.

Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.

M. Kleven, W. Koek, C. Cosi, 1999, Journal of medicinal chemistry.

5-HT1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine.

W. Koek, C. Cosi, M. Assié, 1997, European journal of pharmacology.

(−)-Pindolol and (±)-Tertatolol Affect Rat Hippocampal 5-HT Levels Through Mechanisms Involving Not Only 5-HT1A, But Also 5-HT1B Receptors

W. Koek, M. Assié, 1996, Neuropharmacology.

Is Down-regulation of β-Adrenoceptors Necessary for Antidepressant Activity?

M. Briley, A. Broadhurst, M. Assié, 1988 .

Neuropharmacology of a new potential anxiolytic compound, F 2692, 1-(3′-trifluoromethyl phenyl) 1, 4-dihydro 3-amino 4-oxo 6-methyl pyridazine

C. Palmier, P. Chopin, M. Briley, 2005, Psychopharmacology.

Contrasting Contribution of 5-Hydroxytryptamine 1A Receptor Activation to Neurochemical Profile of Novel Antipsychotics: Frontocortical Dopamine and Hippocampal Serotonin Release in Rat Brain

A. Newman-Tancredi, M. Assié, V. Ravailhe, 2005, Journal of Pharmacology and Experimental Therapeutics.

Depletion of 5-HT Disrupts Prepulse Inhibition in Rats: Dependence on the Magnitude of Depletion, and Reversal by a 5-HT Precursor

M. Kleven, W. Koek, M. Assié, 2002, Neuropsychopharmacology.

Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety

R. Depoortère, P. Heusler, D. Cussac, 2013, Neuropharmacology.

In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat

P. Celada, F. Artigas, A. Newman-Tancredi, 2011, Psychopharmacology.

Dual, Hyperalgesic, and Analgesic Effects of the High-Efficacy 5-Hydroxytryptamine 1A (5-HT1A) Agonist F 13640 [(3-Chloro-4-fluoro-phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-ylmethyl)-amino]-methyl}piperidin-1-yl]methanone, Fumaric Acid Salt]: Relationship with 5-HT1A Receptor Occupancy and Kinetic P

F. Colpaert, A. Newman-Tancredi, W. Koek, 2005, Journal of Pharmacology and Experimental Therapeutics.

Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia

P. Pauwels, F. Colpaert, W. Koek, 2002, Neuropharmacology.

5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential.

P. Pauwels, F. Colpaert, W. Koek, 2001, European journal of pharmacology.

F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential.

P. Pauwels, C. Palmier, F. Colpaert, 1998, The Journal of pharmacology and experimental therapeutics.

The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.

A. Newman-Tancredi, M. Assié, L. Bardin, 2008, European journal of pharmacology.

Neuropharmacology of a new potential anxiolytic compound, F 2692, 1-(3′-trifluoromethyl phenyl) 1, 4-dihydro 3-amino 4-oxo 6-methyl pyridazine

P. Chopin, M. Briley, M. Assié, 2005, Psychopharmacology.

Effects of Repeated Administration of Diazepam to Rats on Locomotor Activity, Elevated Plus-maze and Various Brain Receptors

C. Palmier, P. Chopin, M. Briley, 1991 .

Native Rat Hippocampal 5-HT1A Receptors Show Constitutive Activity

D. Cussac, A. Newman-Tancredi, J. Martel, 2007, Molecular Pharmacology.

F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release.

A. Newman-Tancredi, L. Zimmer, C. Bétry, 2009, European journal of pharmacology.

In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles

A. Newman-Tancredi, M. Assié, N. Consul-Denjean, 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine.

P. Pauwels, C. Palmier, F. Colpaert, 1999, The Journal of pharmacology and experimental therapeutics.

Repeated administration of milnacipran, a new antidepressant, has no effect on a functional β-adrenergic response in the rat brain

M. Briley, A. Stenger, Avital Lann, 1990 .

[3H]‐8‐OH‐DPAT binding in the rat brain raphe area: involvement of 5‐HT1A and non‐5‐HT1A receptors

W. Koek, M. Assié, 2000 .

F15599, a highly selective post-synaptic 5-HT(1A) receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity.

R. Depoortère, F. Colpaert, A. Newman-Tancredi, 2010, The international journal of neuropsychopharmacology.

Preferential in vivo action of F15599, a novel 5‐HT1A receptor agonist, at postsynaptic 5‐HT1A receptors

P. Celada, F. Artigas, A. Newman-Tancredi, 2010, British journal of pharmacology.

Signal transduction and functional selectivity of F15599, a preferential post‐synaptic 5‐HT1A receptor agonist

P. Heusler, D. Cussac, A. Newman-Tancredi, 2009, British journal of pharmacology.

Rapid desensitization of somatodendritic 5‐HT1A receptors by chronic administration of the high‐efficacy 5‐HT1A agonist, F13714: a microdialysis study in the rat

A. Newman-Tancredi, M. Assié, V. Ravailhe, 2006, British journal of pharmacology.

Correlation between low/high affinity ratios for 5-HT(1A) receptors and intrinsic activity.

W. Koek, C. Cosi, M. Assié, 1999, European journal of pharmacology.

In vivo estimates of efficacy at 5-HT1A receptors: effects of EEDQ on the ability of agonists to produce lower-lip retraction in rats

W. Koek, G. Zernig, C. France, 2000, Psychopharmacology.

Anticataleptic properties of α2 adrenergic antagonists in the crossed leg position and bar tests: differential mediation by 5-HT1A receptor activation

A. Newman-Tancredi, M. Kleven, C. Cosi, 2005, Psychopharmacology.

Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats.

M. Kleven, W. Koek, M. Assié, 1997, The Journal of pharmacology and experimental therapeutics.

Effects of 5-HT1A receptor antagonists on hippocampal 5-hydroxytryptamine levels: (S)-WAY100135, but not WAY100635, has partial agonist properties.

W. Koek, M. Assié, 1996, European journal of pharmacology.

Possible in vivo 5‐HT reuptake blocking properties of 8‐OH‐DPAT assessed by measuring hippocampal extracellular 5‐HT using microdialysis in rats

W. Koek, M. Assié, 1996, British journal of pharmacology.

P.3.d.007 F15063, a novel antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: III. Duration of brain D2-like receptor occupancy, antipsychotic-like activity and plasma concentration in rodents

R. Depoortère, A. Newman-Tancredi, M. Kleven, 2006, European Neuropsychopharmacology.

In vivo [3H]ketanserin binding: effect of modifying synaptic serotonin levels

M. Briley, M. Charvéron, M. Assié, 1988, Neurochemistry International.

Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia.

A. Newman-Tancredi, C. Cosi, M. Assié, 2005, The international journal of neuropsychopharmacology.

Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.

A. Newman-Tancredi, C. Cosi, M. Assié, 2006, European journal of pharmacology.

F15063, a potential antipsychotic with D2/D3 antagonist, 5‐HT1A agonist and D4 partial agonist properties: (I) in vitro receptor affinity and efficacy profile

C. Palmier, F. Colpaert, D. Cussac, 2007, British journal of pharmacology.

In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat

P. Celada, F. Artigas, A. Newman-Tancredi, 2012, Psychopharmacology.

5‐HT1A receptors are involved in the effects of xaliproden on G‐protein activation, neurotransmitter release and nociception

R. Depoortère, A. Newman-Tancredi, J. Martel, 2009, British journal of pharmacology.

Estimation of apparent pA2 values for WAY 100635 at 5-HT1A receptors regulating 5-hydroxytryptamine release in anaesthetised rats.

W. Koek, M. Assié, 2000, European journal of pharmacology.